1. Scrip
  2. >>R&D
  3. >>Clinical Trials

In Difficult Times For AAV Gene Therapies, AbbVie Boosts Regenxbio’s Ambitions

Wet AMD Is Challenging Target

 
• By Andrew McConaghie

While other gene therapy companies are scaling back plans or struggling to raise cash, Regenxbio is benefitting from AbbVie’s partnership in wet AMD.

Regenxbio
• Source: Alamy

These are uncertain times for companies looking to develop AAV-based gene therapies, but Regenxbio is doubling down in its focus on the platform, thanks in part to support from partners AbbVie.

Regenxbio’s lead candidate is RGX-314, an AAV8 gene therapy candidate for wet age-related macular degeneration (wet AMD) and diabetic retinopathy, which it believes could eventually displace

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D